Nuo Therapeutics Inc (AURX)
0.7499
0.00 (0.00%)
USD |
OTCM |
May 31, 16:00
Nuo Therapeutics Revenue (Quarterly): 0.2346M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.2346M |
| December 31, 2023 | 0.197M |
| September 30, 2023 | 0.2322M |
| June 30, 2023 | 0.1182M |
| March 31, 2023 | 0.0611M |
| December 31, 2022 | 0.074M |
| September 30, 2022 | 0.0382M |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | |
| December 31, 2019 | 0.0049M |
| September 30, 2019 | 0.0579M |
| June 30, 2019 | 0.0442M |
| March 31, 2019 | 0.0392M |
| December 31, 2018 | 0.8121M |
| September 30, 2018 | 0.2603M |
| June 30, 2018 | 0.1383M |
| March 31, 2018 | 0.1599M |
| December 31, 2017 | 0.1975M |
| September 30, 2017 | 0.1622M |
| Date | Value |
|---|---|
| June 30, 2017 | 0.1886M |
| March 31, 2017 | 0.1727M |
| September 30, 2016 | 0.1768M |
| March 31, 2016 | 1.408M |
| December 31, 2015 | 1.609M |
| September 30, 2015 | 2.169M |
| June 30, 2015 | 2.895M |
| March 31, 2015 | 4.837M |
| December 31, 2014 | 1.898M |
| September 30, 2014 | 1.692M |
| June 30, 2014 | 2.326M |
| March 31, 2014 | 1.846M |
| December 31, 2013 | 3.464M |
| September 30, 2013 | 3.366M |
| June 30, 2013 | 2.424M |
| March 31, 2013 | 2.317M |
| December 31, 2012 | 2.103M |
| September 30, 2012 | 1.759M |
| June 30, 2012 | 3.685M |
| March 31, 2012 | 3.017M |
| December 31, 2011 | 2.955M |
| September 30, 2011 | 1.532M |
| June 30, 2011 | 1.394M |
| March 31, 2011 | 1.366M |
| December 31, 2010 | 1.288M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.0049M
Minimum
Dec 2019
0.2346M
Maximum
Mar 2024
0.1062M
Average
0.0675M
Median
Revenue (Quarterly) Benchmarks
| AIM ImmunoTech Inc | 0.04M |
| Perspective Therapeutics Inc | -- |
| Protalix BioTherapeutics Inc | 3.748M |
| Electromed Inc | 13.87M |
| Armata Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -0.7088M |
| Total Expenses (Quarterly) | 0.9438M |
| EPS Diluted (Quarterly) | -0.02 |
| Enterprise Value | 33.46M |
| Gross Profit Margin (Quarterly) | 78.43% |
| Profit Margin (Quarterly) | -302.2% |
| Earnings Yield | -10.67% |
| Normalized Earnings Yield | -10.67 |